Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.09), Zacks reports. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The firm had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.62 million.
Enanta Pharmaceuticals Stock Down 2.9%
ENTA opened at $10.67 on Tuesday. The business’s 50 day moving average is $11.88 and its 200-day moving average is $13.07. Enanta Pharmaceuticals has a twelve month low of $10.05 and a twelve month high of $17.15.
Wall Street Analyst Weigh In
ENTA has been the subject of a number of research analyst reports. Wall Street Zen downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $20.00.
View Our Latest Analysis on ENTA
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.
Featured Stories
- Five stocks we like better than Enanta Pharmaceuticals
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
